1. Home
  2. WVE vs UPBD Comparison

WVE vs UPBD Comparison

Compare WVE & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • UPBD
  • Stock Information
  • Founded
  • WVE 2012
  • UPBD 1986
  • Country
  • WVE Singapore
  • UPBD United States
  • Employees
  • WVE N/A
  • UPBD N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • UPBD Diversified Commercial Services
  • Sector
  • WVE Health Care
  • UPBD Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • UPBD Nasdaq
  • Market Cap
  • WVE 915.6M
  • UPBD 1.0B
  • IPO Year
  • WVE 2015
  • UPBD 1995
  • Fundamental
  • Price
  • WVE $7.35
  • UPBD $17.26
  • Analyst Decision
  • WVE Strong Buy
  • UPBD Strong Buy
  • Analyst Count
  • WVE 14
  • UPBD 4
  • Target Price
  • WVE $20.50
  • UPBD $32.50
  • AVG Volume (30 Days)
  • WVE 3.6M
  • UPBD 980.8K
  • Earning Date
  • WVE 11-10-2025
  • UPBD 10-30-2025
  • Dividend Yield
  • WVE N/A
  • UPBD 8.97%
  • EPS Growth
  • WVE N/A
  • UPBD N/A
  • EPS
  • WVE N/A
  • UPBD 1.45
  • Revenue
  • WVE $109,230,000.00
  • UPBD $4,577,844,000.00
  • Revenue This Year
  • WVE N/A
  • UPBD $10.26
  • Revenue Next Year
  • WVE $6.24
  • UPBD $7.68
  • P/E Ratio
  • WVE N/A
  • UPBD $11.98
  • Revenue Growth
  • WVE 103.75
  • UPBD 7.48
  • 52 Week Low
  • WVE $5.28
  • UPBD $15.82
  • 52 Week High
  • WVE $16.38
  • UPBD $36.00
  • Technical
  • Relative Strength Index (RSI)
  • WVE 49.41
  • UPBD 37.25
  • Support Level
  • WVE $6.60
  • UPBD $15.82
  • Resistance Level
  • WVE $7.27
  • UPBD $17.22
  • Average True Range (ATR)
  • WVE 0.53
  • UPBD 0.74
  • MACD
  • WVE -0.04
  • UPBD 0.07
  • Stochastic Oscillator
  • WVE 51.78
  • UPBD 37.05

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: